Patient P-01423

Synthetic patientNBL-101 · Day 91 · 35–44 · F · baseline S19Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Declining

Discontinuation risk

66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S19
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −22% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 58 GI-04 recommended — GI Support Protocol GI-04
Day 58 ME-01 recommended — Monitoring Escalation ME-01
Day 59 Patient accepted — Started GI-04 in the companion
Day 59 Patient accepted — Started ME-01 in the companion
Day 62 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 67 GI symptom burden −30% vs expected — GI Support Protocol GI-04
Day 73 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

Inflammatory activity+14
Treatment adherence-14
GI instability+9
Nutritional resilience-6
Toxicity+5

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −22%
GI Support Protocol GI-04Day 58
Result: symptom burden −30%
Monitoring Escalation ME-01Day 58
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

65%

probability of meaningful tolerance improvement

284 similar trajectories
81% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

49.3/100

worsening · +2.4 vs previous 14 d

Toxicity

Blood

42.8/100

worsening · +7.6 vs previous 14 d

Sleep quality

Wearable

34.9/100

worsening · -3.6 vs previous 14 d

Energy level

Daily log

3.7/10

worsening · -0.4 vs previous 14 d

Stress level

Daily log

6.5/10

worsening · +0.4 vs previous 14 d

Steps

Wearable

3,791

worsening · -378 vs previous 14 d

Adherence

Companion

47.7 %

worsening · -21.2 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 29 from the failing basin, 58 from restoration.

Would help

SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 65%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 65%

Would not help

Keep histamine low
GI +4.2 next day on high-intake days · n 22
Keep alcohol low
GI +2.5 next day on high-intake days · n 12
Keep simple carbs low
GI +2.4 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+4.2detractor · 95%
Alcohol
+2.5detractor · 88%
Simple carbohydrates
+2.4detractor · 82%
Spicy / capsaicin
+1.3no signal · 42%
Insoluble fibre
+1.2no signal · 35%
Dietary fat load
-0.8no signal · 20%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 49 and rising
- WearableSleep 6.1 h, below personal baseline
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 57
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 43
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓40
- Wearable3,791 steps/day
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 2.2 · butyrate capacity 45/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 6.4 h
Steps: 5,203
Resting HR: 68 bpm

Daily log: GI score 49, nutritional resilience 44, adherence 48.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01386	23%	S13	—	—	70
P-01750	24%	S16	—	—	69
P-01699	28%	S04	GI-04	improved	69
P-01508	24%	S18	—	—	68
P-01509	24%	S17	—	—	68
P-01875	24%	S11	—	—	67
P-01877	25%	S01	CR-01	improved	67
P-01515	23%	S16	—	—	66
P-01629	24%	S19	—	—	66
P-01714	29%	S14	GI-04	improved	66
P-01858	30%	S14	NP-02	improved	65
P-01317	25%	S19	—	—	65